Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA4 | P22748 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | IGLV6-57 | P01721 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 4/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13338103 | 0.88 | CA12 (0.63) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13627686 | 0.78 | CA12 (0.50) | CA12CA1CA2CA4CA9 | |
| SCHEMBL17076687 | 0.77 | CA12 (0.58) | CA12CA1CA2CA4CA9 | |
| SCHEMBL121718 | 0.77 | CA12 (0.53) | CA12CA1CA2CA4CA9 | |
| SCHEMBL10430153 | 0.76 | CA12 (0.52) | CA12CA1CA2CA4CA9 | |
| SCHEMBL10126418 | 0.75 | CA1 (0.51) | CA12CA1CA2CA4CA9 | |
| SCHEMBL23960143 | 0.74 | CA12 (0.50) | CA12CA1CA2CA4CA9 | |
| SCHEMBL21755799 | 0.74 | CA12 (0.50) | CA12CA1CA2CA4CA9 | |
| SCHEMBL28417341 | 0.74 | PYCR1 (0.60) | CA12CA1CA2CA4CA9 | |
| SCHEMBL978318 | 0.73 | CA12 (0.48) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117873-B2 | Oxazine compound, composition, and cured product | DIC CORPORATION (JP) | 2021-09-14 | — | — | US | disclosed |
| US-20180362480-A1 | OXAZINE COMPOUND, COMPOSITION, AND CURED PRODUCT | DIC CORPORATION (JP) | 2018-12-20 | — | — | US | disclosed |
| EP-3388461-A1 | OXAZINE COMPOUND, COMPOSITION, AND CURED PRODUCT | DIC Corporation (JP) | 2018-10-17 | — | — | EP | disclosed |
| US-20130178600-A1 | POLY(ETHYLENE GLYCOL) DERIVATIVES FOR CLICK CHEMISTRY | INTEZYNE TECHNOLOGIES, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8268936-B2 | Synthesis of hybrid block copolymers and uses thereof | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120226050-A1 | POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-8212083-B2 | Use in PEGylation of biologicals; variety of terminal functional groups; made by polymerizing ethylene oxide on initiators such as N-(hydroxyalkyl) imines or N,N-bis(diphenyloxophosphino)-N-hydroxyalkylamines | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8207353-B2 | Poly(ethylene glycol) containing chemically disparate endgroups | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20110224383-A1 | POLY(ETHYLENE GLYCOL) DERIVATIVES FOR METAL-FREE CLICK CHEMISTRY | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7893277-B2 | Poly(ethylene glycol) containing chemically disparate endgroups | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20110021718-A1 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF | INTEZYNE TECHNOLOGIES (US) | 2011-01-27 | — | — | US | disclosed |
| US-20100280252-A1 | POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS | INTEZYNE TECHNOLOGIES (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100160645-A1 | POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS | INTEZYNE TECHNOLOGIES, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-7612153-B2 | conjugate polymer drugs; endcapped polyethers; nontoxic, biocompatible, non-immunogenic, soluble in water and other solvents | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7601796-B2 | polyamideether copolymer has a hydrophilic polyethylene glycol and a hydrophobic polyamino acid blocks; modified polyethylene glycol homopolymer; forming conjugate polymer drug; resin peptides; use in pharmaceutically acceptable compositions | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7560588-B2 | Poly(ethylene glycol) containing chemically disparate endgroups | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20080207913-A1 | Poly(ethylene glycol) containing chemically disparate endgroups | INTEZYNE TECHNOLOGIES (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080188638-A1 | Heterobifunctional poly(ethyleneglycol) containing acid-labile amino protecting groups and uses thereof | INTEZYNE TECHNOLOGIES (US) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280252-A1 | POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS | GNE, EPRS1, ALG1 | CA12 1126/4885CA1 2195/4885CA2 3187/4885 |
| US-20100160645-A1 | POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS | GNE, EPRS1, ALG1 | CA12 1126/4885CA1 2195/4885CA2 3187/4885 |
| US-20080188638-A1 | Heterobifunctional poly(ethyleneglycol) containing acid-labile amino protecting groups and uses thereof | LNPEP, GNE, DNPEP | CA12 701/4885CA1 793/4885CA2 2008/4885 |
| US-20180362480-A1 | OXAZINE COMPOUND, COMPOSITION, AND CURED PRODUCT | KDM5A, WDR5, SMC4 | CA12 553/4885CA1 377/4885CA2 1404/4885 |
| US-20120226050-A1 | POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS | GNE, EPRS1, ALG1 | CA12 1126/4885CA1 2195/4885CA2 3187/4885 |
| US-11117873-B2 | Oxazine compound, composition, and cured product | KDM5A, WDR5, SMC4 | CA12 553/4885CA1 377/4885CA2 1404/4885 |
| US-20080207913-A1 | Poly(ethylene glycol) containing chemically disparate endgroups | GNE, EPRS1, ALG1 | CA12 1126/4885CA1 2195/4885CA2 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.